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hemodialysis with and without (abst) 579
transfer, high-flux vs. PFD (abst) 570
Acid-base regulation, CAPD 48:S-47
Acidosis
bone nodule formation 1199
distal renal tubular (abst) 1745
muscle protein synthesis 1705
Acquired renal cystic disease 951
Acute hantavirus nephropathy (abst) 1468
Acute leukemia, chlorambucil, post-transplant (abst) 933
Acute metabolic alkalosis, tubular adaptation (abst) 561
Acute pyelonephritis
blood groups and HLA DQA (abst) 1746
children, risk factors (abst) 935
E. coli kills human renal cells 1083
IL-6, stress hormone responses (abst) 930
Acute renal failure
bone marrow transplantation, Nephrology Forum 1443
children, multicenter study, Spain (abst) 564
cyclic RGD peptides, rats 1050
glycerol-induced, PAF antagonist, nifedipine (abst).... 1748
hemorrhagic arterial pressure reduction 318
intensive care units, mortality rates (abst) 564
intensive care units, treatment/prognosis (abst) 563
kidney cell membrane proteins 47:S-52
mortality, predictive factors (abst) 564
post-ischemic protective effect, L-arginine (abst) 1747
rhabdomyolysis (abst) 565
scleroderma renal crisis (abst) 563
secondary, salmonella enteritidis (abst) 565
Acute renal papillary necrosis, urinary enzymes 47:S-60
Acyclovir, glomerular hemodynamics, rats (abst) 1748
Adenomas, aldosterone-producing and renin gene 1591
Adenosine infusion, renal effect (abst) 1459
Adhesion molecules
complement non-activating membranes (abst) 1243
peripheral lymphocytes, OKT3 therapy (abst) 1468
vascular endothelin expression, granulomatous
vasculitis (abst) 1463
Adolescents, IDDM, plasma prorenin, DN 1154
Adrenal renin, transgenic rats 1583
Adrenergic receptors, hypotensive HD patients (abst) .... 574
Adriamycin nephrosis
ACEi, hippuran handling, rats (abst) 1463
ACEi, proteinuria, rats (abst) 1467
Advanced glycosylation end products
G-6-P, diabetic nephropathy (abst) 939
immunological quantification, dialysis 216
isolated, lactoferrin binding (abst) 939
Adynamic bone after intermittent calcitriol 1160
Aerotolerant coryneforms, UT! (abst) 928
Afferent arteriolar response, Ang II, DM, rats (abst) . . . . 1460
AIDS
glomerular alteration (abst) 559
nephropathy, epidemiology, tropical regions (abst) .... 1247
renal infection, HIVAN 16
ALA-dehydrase, HD membranes, erythrocytes (abst) 566
Albumin
glomeruli, C5b-9 increases permeability 382
LCAT activity, lipoprotein phospholipids 97
losses during HD 830
Albuminuria
anti-GBM nephritis, platelets, fibrin (abst) 1462
children, rHGH (abst) 559
enalapril, Losartan, mAb, aminopeptidase (abst) 1467
Aldosterone
adenomas producing, renin gene 1591
Na transport, distal A6 cells (abst) 1246
Alkaline phosphatase, as urinary marker 47:S-43
Alkalosis, tubular adaptation (abst) 561
Allogenic immune response, chronic Al toxicity (abst) ... 1744
Allografts
acute rejection, eosinophil role (abst) 933
chronic rejection, EGF 1207
chronic rejection, TGFp1 expression (abst) 933
ICAM-1 expression in parenchymal cells (abst) 1743
monoclonal antibodies, Nephrology Forum 540
Alport syndrome
COL4A5 germ-line mutation 1307
collagen type IV gene frameshift mutation (abst) 1461
detection of mutations (abst) 940
Aluminum
dialysis fluids as source of (abst) 587
Fe gluconate, phospho-Ca metabolism, HD (abst) 575
histomorphometric effects, rats (abst) 587
removal 587, 1461
Aluminum intoxication
experimental, natural cell cytotoxicity (abst) 1751
lymphocyte subsets, allogenic immune response (abst) . 1744
Aluminum-related bone disease
HD patients (abst) 1751
low-dose desferrioxamine, HD (abst) 1461
Ambulatory blood pressure monitoring
compared, pre- and post-dialytic BP (abst) 571
CRF, chronic GN, interstitial nephritis (abst) 556
hemodialysis patients (abst) 567
Amino acids
losses during HD 830
losses during HD, membrane effect (abst) 567
renal handling, renal functional reserve (abst) 1246
Aminopeptidase mAb, enalapril, Losartan (abst) 1467
Animoniagenesis, PGF2, Na/H transport 1069
Amphotericin B, proximal tubular toxicity (abst) 936
Am'loidosis
scans (abst) 568
131I-f32-M radionuclide imaging (abst) 568
/32-M, as aniyloid protein, HD (abst) 577
J32-M, membrane absorption 1140
Central Australian Aborigines (abst) 928
ANA antibodies, ANCA-associated diseases (abst) 938
Analgesics with phenacetin, renal pelvis cancers (abst). . . . 925
1791
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Anemia
iron kinetics/balance, rHuEPO, HD (abst) 577
long-term treatment, predialysis, CRF (abst) 558
renal insufficiency, s.c. rHuEPO (abst) 561
Angeitis, with rapidly progressive ON (abst) 1242
Angiography, magnetic resonance, PKD (abst) 559
Angioplasty
atherosclerotic renovascular disease (abst) 556
thrombosed HD access sites 1375
Angiotensin converting enzyme (ACE), rHuEPO, HD
(abst) 570
Angiotensin converting enzyme (ACE) inhibition
antiproteinuric effect, diet (abst) 1465
BP reduction, proteinuria, rats (abst) 1464
Ca blockade, renal artery stenosis, hypertension 421
glomerular protein synthesis, DN (abst) 934
hippuran handling, adriamycin nephrosis, rats (abst)... 1463
hippurate handling, renovascular hypertension (abst) .. 1472
proteinuria, adriamycin nephrosis, rats (abst) 1467
Angiotensin II (Ang II)
afferent arteriolar response, DM, rats (abst) 1460
blockade, rats with reduced renal mass 980
hormonal regulation, angiotensinogen 1561
isoproterenol-induced fos in rat brain 1567
Angiotensin II (Aug II) receptor type 1
abnormality in Bartter's syndrome 1505
characterization of mutant clone 1580
desensitization/regulation of function 1499
hypertension, renal injury in SHRSP 1346
Angiotensin II (Aug II) receptor type 1A 1492
Angiotensin II (Ang II) receptor type 2 1502
Angiotensin II (Aug II) receptor type 4 1510
Angiotensin II (Aug II) receptors
glucocorticoid uncoupling from PLC 675
internalization and signaling requirements 1496
localization, renomedullary interstitial cells 1483
losartan, plasma renin, natriuresis 1479
pharmacology in the kidney 1486
proximal tubule expression, DM 1603
renin release, afferent arterioles, rats 1570
subtypes, AT1 receptor mRNA, rat kidney 973
Angiotensinogen
cellular/ultrastructural renal location 1557
gene expression, cortical, transgenic mice 1533
gene expression, isoproterenol, cAMP 703
hormonal regulation, Aug II 1561
renin gene, aldosterone-producing adenomas 1591
renin secretion, adrenal, retinal, transgenic rats 1583
renin secretion, endothelium-mediated 1577
tissue specific regulation, glucocorticoids, cAMP 1574
transcription factors, gene expression, hepatocytes . . . . 1564
Anti-cardiolipin antibodies, ANCA diseases (abst) 938
Anti-GBM antibodies
ANCA diseases (abst) 938
Goodpasture's syndrome 823
Anti-GBM nephritis, albuminuria, fibrin (abst) 1462
Anti-myeloperoxidase (MPO)
ANCA affinity, systemic vasculitis 177
anti-LF and anti-histone antibodies, vasculitis 153
antibodies, ANCA-associated diseases (abst) 939
differential binding, PR3, HUVEC monolayers (abst).. 1462
necrotizing crescentic ON, renal ischemia (abst) 1459
Anti-neutrophil cytoplasm antibodies (ANCA)
anti-myeloperoxidase affinity 177
antigen specificity 153
cytokines, vasculitis, IgA nephropathy (abst) 1744
diagnostic/pathophysiologic potential 1
diseases of, epitope mapping, antibodies (abst) 939
diseases of ANA, ACL, anti-GBM antibodies (abst). .. . 938
extracapillary glomerulonephritis (abst) 559
HLA class II, HD (abst) 579
mediated ADCC of PR3/MPO incubated HUVEC
(abst) 1462
AfltNform antibody, HD patients (abst) 924
Anti-oxidative LDL autoantibodies, uremia, HD 869
Anti-proteinase 3 antibodies, ANCA diseases (abst) 939
Anti-Thy-i nephritis, CD59, vitronectin, C5b-9 (abst).... 1461
Antibodies
ANCA-associated diseases (abst) 938, 939
anti-131 integrin molecule in ATO (abst) 1245
anti-Gal, xenotransplantation (abst) 932
anti-Nrm, HD patients (abst) 924
anticardiolipin, HD (abst) 571
GBM, Goodpasture's syndrome 823
HCV, CRF, impaired immunity (abst) 556
HCV, CRF, nondialyzed patients (abst) 556
HCV, HD patients (abst) 569
HCV, predialysis prevalence (abst) 557
HCV, primary glomerulonephritis (abst) 1748
helicobacter pilori, HD (abst) 569
HTLV-1, HD patients (abst) 922
lactoferrin, histone, vasculitis 153
oxidative LDL, uremia, HD 869
post-hepatitis B vaccination (abst) 1246
VLA-4 integrin, HgCl2-induced nephritis, rats (abst) ... 559
Anticardiolipin antibodies, HD (abst) 571
Antigens
activation, lymphocyte subsets, rejection (abst) 586
natural killer cells, differing membranes (abst) 578
Antilymphoblast globulin, OKT3 therapy (abst) 583, 584
Antisense inhibition, hypertension, RAS 1554
Antithymocyte globulins, integrin antibodies (abst) ... 1245
Apoptosis
gentamicin toxicity, regeneration (abst) 1462
renal injury, SGP-2 gene, regeneration (abst) 926
Arginine-glycine-aspartic acid, peptides, ARF, rats 1050
Arginine vasopressin antagonist in cirrhotic rats 237
Arterial pressure
hypertension, transplantation (abst) 585
reduction in ARF 318
Atherosclerosis
immune reactions 869
lipoproteins, renal replacement therapy (abst) 929
renovascular, angioplasty, captopril renography (abst)... 556
ATP-induced Ca transport inhibition (abst) 1459
Atrial natriuretic peptide (ANP)
renal/vascular permeability, DM (abst) 1460
volume loads, BNP, CRF (abst) 936
Autonomic nervous system, hypotension, HD (abst) 574
Autosomal dominant polycystic kidney disease (ADPKD)
hypertension pathogenesis 1118
progression to renal failure (abst) 1246
Azathioprine vs. CsA, post-cadaver transplant (abst) .... 1465
B
Bacterial
endotoxins, different HD filters (abst)
risk, BiCart concentrate storage (abst)
Bancroftian filariasis, DEC therapy (abst)
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Bence-Jones proteins
nephropathogenicity, structural features 47:S-93
nephrotoxicity, EC acidification (abst) 1753
Beta adrenergic stimulation reduces serum K, HD (abst). 1738
13-fibroblast growth factor, HIV nephropathy 759
13 integrin molecule antibodies, ATG 1245
/32-microglobulin
as amyloid protein, amyloidosis, HD (abst) 577
membrane absorption 1140
radionuclide imaging, amyloidosis (abst) 568
Bicarbonate buffers in hemodialysis 1167
Bicarbonate transport
Cl-dependent, cortical distal tubule, rats (abst)
high-flux vs. paired filtration dialysis (abst)
BiCart dialysis concentrate, storage (abst)
Bienergetic radiographic absorptiometry, HD (abst)
Bilateral ureteral obstruction, dietary protein
Biocompatibility
membranes, evaluation, clearances (abst) 1470
membranes, granulocyte surface receptors (abst) 575
membranes, protein production (abst) 570
peritoneal dialysis fluid, CAPD 48:S-69
Bioimpedance analysis
monitors body fluid variation, RXc graph 534
total body water, HD 1438
Biopsy. See Renal biopsy
Blood groups, HLA DQA and acute pyelonephritis
(abst) 1746
Blood pressure
ACEi, proteinuria, hypertension, rats (abst) 1464
bradykinin inhibition, hyperinsulinemia (abst) 1739
digoxin-like inhibitors, active sodium transport 297
glucose metabolism, insulin, salt overload (abst) 1739
L-arginine, hypertension, dietary salt (abst) 1739
radiotelemetric monitoring, antihypertensives 1010
renal sodium handling, insulin, NIDDM (abst) 1471
Blood viscosity, enalapril, hypertension (abst) 924
Blood volume
non-invasive measurement, optical techniques (abst). . . . 941
regulation, children, minimal lesion NS (abst) 1470
Body weight loss, proteinuria, captopril (abst) 562
Bone disease
adynamic, calcium kinetics 855
adynamic, intermittent calcitriol therapy 1160
aluminum, HD patients (abst) 1751
aluminum, low-dose desferrioxamine, HD (abst) 1461
calcium kinetics 855
inhibited mineralization, acidosis 1199
metabolic, CAPD 48:S-51
metabolic, osteocalcin, CAPD 838
osseus mass evolution, HD (abst) 574
spine, analysis on autopsy 733
Bone marrow
suppression, parvovirus, post-transplant (abst) 923
transplantation, ARF, Nephrology Forum 1443
Bone mineral density
densitometry, renal lithiasis treatment (abst) 1740
hypercalciuria, children (abst) 1743
idiopathic hypercalciuria (abst) 1744
Bone radiology, hyperparathyroidism, vitamin D (abst) . . . 569
Bone turnover markers, secondary HP, CRF (abst) 561
Bradykinin inhibition, insulin resistance, BP (abst) 1739
Brain natriuretic peptide, volume loads, CRF (abst) 936
Buffers
effects in hemodialysis 1167
ultrafiltration, LV performance, HD (abst) 1738
C
c-fos and c-fun, glucose, ECM, MC cultures 105
C-type natriuretic peptide
glomerular receptors, human MC 717
human kidney and urine 744
renal function, sheep (abst) 934
C4 production, mesangial cells, cytokines (abst) 1468
Ca2, captopril, in mesangial cells 696
Ca2 channel blockers, anoxic proximal tubule injury 223
Cadaver transplants
complement activation, ischemia reperfusion (abst). . . . 1745
CsA maintenance monotherapy (abst) 1242
CsA vs. azathioprine (abst) 1465
HCV, U.S. Collaborative Study 886
Cadmium toxicity, early urinary markers 47:S-81
Calcineurin, FK506 inhibits Na47K-ATPase 647
Calcitriol
biological action, RF 605
intermittent therapy, adynamic bone 1160
intravenous, chemical parathyroidectomy, HD (abst)... 1752
intravenous, secondary HP, EPO (abst) 576
intravenous bolus, secondary HP (abst) 574
intravenous long-term, chronic uremia, HD 1124
oral pulse therapy, secondary HP (abst) 1751, 1752
post-transplant hyperparathyroidism (abst) 581
PTH levels, phosphorus, renal failure (abst) 563
receptor, nuclear uptake, uremic ultrafiltrate 129
Calcium
blockade, ACEi, RAS, 2K-iC rat hypertension 421
cellular, anoxic proximal tubule injury 223
cytosolic surges, vascular smooth muscle cells 1653
dialysate concentration, hyperparathyroidism (abst) .... 574
kinetics, renal osteodystrophy 855
phosphorus, aluminemia, Fe gluconate, HD (abst) 575
PTH relationship curve, CRF, in vivo 1713
release-activated Ca influx, MC 122
response to PTH, downregulation, uremia 310
transport, ATP-induced inhibition (abst) 1459
urinary acidification, PTH (abst) 1744
Calcium acetate and Ca carbonate
compared, HD (abst) 941
serum phosphate control, HD (abst) 573
Calcium oxalate nephrolithiasis 847
Cancer
renal cell, in situ cytokine expression (abst) 1745
renal pelvis, phenacetin analgesics (abst) 925
skin, post-transplant (abst) 925, 1472
Captopril
inhibits Ca2 in mesangial cells 696
obesity, proteinuria, body weight loss (abst) 562
renography, renovascular atherosclerosis (abst) 556
Cardiac renin is kidney-derived (abst) 1460
Cardiac xenotransplantation (abst) 1750
Cardiovascular disease
molecular biology, genetics 1546
risk factors, children/young adults, ESRD (abst) 921
risk factors, dialyzed uremia 807
risk factors, management, CAPD patients 48:S-31
Cathepsin B, urinary excretion, as tubular marker .... 47:S-64
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CD59
experimental glomerulonephritis 191
inactivates C5b-9, anti-Thy-i nephritis (abst) 1461
Charge selectivity and urine amylase isoenzymes 47:S-89
Chelating agents, compared (abst) 587
Children
Aboriginal, renal disease (abst) 928
acute pyelonephritis, risk factors (abst) 935
ARF, multicenter study, Spain (abst) 564
blood volume regulation, minimal lesion NS (abst).... 1470
bone mineral density, hypercalciuria (abst) 1743
cardiovascular risk factors, renal disease (abst) 921
CRF, energy expenditure (abst) 927
CRF, liquid chromatography, plasma gamma-carboxy
glutamic acid (abst) 560
CRF, rhGH therapy, IGFBP changes (abst) 932
glomerulonephritis, optical microscopy (abst) 1247
idiopathic NS, cyclosporine (abst) 1746
nephrolithiasis, multicenter study, Brazil (abst) 1741
nephrotic syndrome, lipid peroxidation (abst) 1745
peritonitis, CAPD (abst) 1746
renal involvement with UTI (abst) 1750
screening renal abnormalities (abst) 928
T lymphocyte function, NS (abst) 940
urinary albumin elimination, rHGH (abst) 559
vesicoureteric reflux, subureteric Polytef, (abst) 922
Chlorambucil
post-transplant, acute leukemia (abst) 933
pulse cyclophosphamide, membranous nephropathy
(abst) 1465
Cholesterol, hepatic metabolism, uremia 358
Cholesteryl ester transfer
chronic renal failure (abst) 929
renal disease 1147
Chronic renal failure
ambulatory BP monitoring (abst) 556
ANP, BNP, volume loads (abst) 936
bone turnover markers, secondary HP (abst) 561
children, energy expenditure (abst) 927
children, rhGH therapy, IGFBP changes (abst) 932
cholesteryl ester transfer (abst) 929
creatol 47:S-22
dietary protein, multicenter study (abst) 561
HCV antibodies, impaired immunity (abst) 556
HCV antibodies, nondialyzed patients (abst) 556
hypercholesterolemia, pravastatin therapy (abst) 562
IGF-I, renal function 201
iron tubulotoxicity, proteinuria (abst) 932
kidney cell membrane proteins 47:S-52
phosphcalcium metabolism, low-protein diet (abst).... 1243
platelet aggregation, HD (abst) 578
predialysis anemia therapy (abst) 558
PTH, phosphorus-protein restriction 1381
PTH/calcium relationship curve, in vivo 1713
retinol binding protein, serum (abst) 1749
retinol binding protein, urinary (abst) 1748
rHuEPO response factors, HD (abst) 1753
skeletal muscle metabolism/recovery (abst) 921
tubular silicon accumulation (abst) 925
Cilazapril, renal hemodynamics, diabetes (abst) 1740
Cirrhosis
experimental, AVP antagonist OPC-31260, rats 237
renal hypertrophy, rat models (abst) 937
C1 permeability, aldosterone, distal A6 cells (abst) 1246
Cl-dependent bicarbonate transport, distal tubule (abst). . 1742
Clara cell protein, as proximal tubule marker 47:S-34
Clusterin expression, CsA nephrotoxicity (abst) 843, 943
Coagulation
glucocorticosteroids, OKT3 coagulopathy 1596
proteins C and S, HD (abst) 565
COL4A5, germ-line mutation, Alport syndrome 1307
Collagen type III, glomerulopathy (abst) 937
Collagen type IV
al-5 chains, hereditary nephritis 1413
detection in human urine, GN 1431
frameshift gene mutation, Alport syndrome (abst) .... 1461
Collagen type VIII, DN, mast cells (abst) 937
Collecting ducts, water channel gene mutation, diabetes
insipidus (abst) 1467
Complement activation
DAF and MCP synthesis, human MC 986
glomerular neutrophil recruitment, GN (abst) 926
ischemia reperfusion, post-cadaver transplant (abst)... 1745
soluble CR-i inhibition on dialysis membrane 1680
Complement cascade, CSb-9, glomerular albumin
permeability 382
Complement factor B, MC, cytokines (abst) 1468
Complement-independent neutrophil accumulation,
glomerular injury 79
Complement non-activating membranes, granulocytes,
adhesion molecules (abst) 1243
Complement regulatory proteins in kidney 89
Connexin43 in rat kidney 621
Continuous ambulatory peritoneal dialysis (CAPD)
acid-base regulation 48:S-47
adequacy 48:S-2, 48:S-18
adequacy, compared to HD (abst) 1746
adequacy, delivery assessment (abst) 940
advanced glycosylation end products 216
assessing efficiency during 48:S-7
bacterial challenge, peritoneal cavity (abst) 942
bone disease, treatment 48:S-51
cardiovascular risk factors 48:S-31
complications (abst) 580
dialysis fluid biocompatibility 48:S-69
dipyridamole-thallium tests (abst) 1753
effluents, interferon-y levels, peritonitis 475
growth hormone effects 1178
home automated 48:S-25
hyaluronan, source/significance 527
Icodextrin clinical trial 496
immunohistology, peritoneal membrane 443
lipoprotein alterations (abst) 582
low sodium dialysate, fluid/solute transport (abst) 1471
multicenter registry (abst) 581
nasal carriers, S. aureus (abst) 580, 1738
nutrition, compared HD (abst) 567
nutrition, dialysis adequacy (abst) 1739
nutrition, dietary interview (abst) 582
nutrition, optimal 48:S-39
osteocalcin, metabolic bone disease 838
peritoneal clearance, intact PTH (abst) 579
peritoneal host defenses 48:S-58
peritoneal membrane functions 48:S-61
peritoneal transport macromolecules (abst) 1467
peritonitis, children (abst) 1746
peritonitis, initial episode, racial factors 1392
peritonitis, patient characteristics (abst) 580
pregnancy, compared to HD (abst) 1746
register, program study, Spain (abst) 580
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RRF, PCR and KTV correlation (abst) 580
ten year study, Brazil (abst) 1747
TNF-a and soluble TNF-receptors I and II 1422
ultrafiltration failure 48:S-14
ultralow sodium dialysate 333
urea and creatinine kinetics, methods (abst) 581
Coronary disease, molecular biology, genetics 1546
Cortical collecting system, ATP, Ca transport inhibition
(abst) 1459
Cortical distal tubule, bicarbonate transport (abst) 1742
Cortical expression
angiotensinogen gene 1533
tissue factor pathway inhibitor (abst) 942
Creatinine
renal clearance, compared iothalamate (abst) 922
urea kinetics, CAPD (abst) 581
Creatol and chronic renal failure 47:S-22
Crescentic glomerulonephritis
anti-MPO necrotizing, renal ischemia (abst) 1459
delayed-type hypersensitivity mechanisms 69
IL-iRa suppression, rats (abst) 926
plasminogen activator inhibitor-i, rabbits (abst) 927
tissue factor expression (abst) 934
Cross linked fibrin, d-dimer detection by plasmin 260
Cryptococcosis after transplantation (abst) 1244
Cuprophan membranes, granulocytes, adhesion
molecules (abst) 1243
Cutaneous manifestations, transplantation (abst) 925
Cyclic adenosine monophosphate (cAMP)
angiotensinogen regulation, glucocorticoids 1574
fibronectin gene expression, TGFI31, hyperglycemia.... 1019
isoproterenol ANG gene expression, OK 27 cells 703
phosphodiesterase isozyme, superoxidation 28
Cyclic GMP
linked pathway for renin secretion 1588
MC fibronectin synthesis, thromboxane 1074





induction of fibrogenesis (abst) 583
macrophages, MC proliferation, Thy-1.1 model (abst)... 937
nephrotoxicity, nitric oxide 773
nephrotoxicity, psoriasis patients 1216
nephrotoxicity and PDGF 726
pravastatin, hypercholesterolemia (abst) 584
transplant recipient profile changes (abst) 585
Cyclosporin A
compared, azathioprine, cadaver transplant (abst) 1465
concentrations, grapefruit juice (abst) 1468
endothelin secretion, tubular cells (abst) 584
monotherapy, cadaver transplant (abst) 1242
nephrotoxicity, sodium ingestion, rats (abst) 584
Cyclosporine
compulsory withdrawal, post-transplant (abst) 1751
early treatment prevents GS, lupus nephritis 1663
idiopathic nephrotic syndrome, children (abst) 1746
Cyclosporine A
delayed hypersensitivity reaction (abst) 1745
nephrotoxicity, clusterin expression (abst) 843, 943
Cystatin C serum concentration, determines GFR.... 47:S-17,
47:S-20
Cystatins, urinary excretion, as tubular marker 47:S-64
Cysteinyl leukotriene excretion, glomerulonephritis 1322
Cystic disease, renal, hereditary and acquired 951
Cytokines
expression, IgA nephropathy, ANCA vasculitis (abst).. 1744
focal GS, fibronectin, low protein diet (abst) 938
focal GS, remnant kidney model (abst) 938
HILDA/LIF secretion, infections post-transplant (abst). 1243
introduction, high flow membrane HD (abst) 566
macrophage-derived, induce cyclooxygenase mRNA.... 900
MC production, complement factor B and C4 (abst)... 1468
in situ expression, renal cell carcinoma (abst) 1745
Cytomegalovirus, OKT3 therapy, transplantation (abst) ... 582
Cytosolic phospholipase A2, ET-i, glomerular MC, rats.. 1644
Cytotoxicity, natural cell and Al intoxication (abst) 1751
D
D-dimer detected by plasmin 260
Decay accelerating factor, human MC synthesis,
complement activation 986
Delayed type hypersensitivity reaction, CsA (abst) 1745
Deoxyspergualin, macrophage proliferation, allograft
rejection, rats (abst) 922
Desferrioxamine
aluminum-related bone disease, HD (abst) 1461
aluminum removal, HD (abst) 587
compared, 1,2-dimethyl-3-hydroxidpyrid-4-one (abst) ... 587
nephrotoxicity, thalassemic patients 467
Diabetes
exercise, microalbuminuria, young subjects (abst) 1749
MC synthesis, glycosaminoglycan, rats (abst) 1752
murine, renal TGF-p content 748
nephrotic range proteinuria remission 1688
renal hemodynamics, hypertension, cilazapril (abst) . . . 1740
Diabetes insipidus
gene mutation, renal CD water channel (abst) 1467
hydrocholorthiazide, water absorption (abst) 1742
mutations in V2 receptor gene 170
Diabetes mellitus
afferent arteriolar response, Ang II, rats (abst) 1460
charge selectivity, urine amylase isoenzymes 47:S-89
high glucose, ECM proteins, in MC cultures 105
post-transplant, risk factors (abst) 1743
proximal tubule Ang II receptor expression 1603
renal/vascular permeability, ANP (abst) 1460
retinopathy, urinary excretion of RBP 47:S-105
Diabetic nephropathy
ACEi, glomerular protein synthesis (abst) 934
antihypertensives, mesangial volume expansion 161
collagen type VIII, mast cells (abst) 937
diagnostic strategy to monitor 47:S-109
endocrinology/nephrology follow-up (abst) 558
G-6-P, advanced glycosylation end products (abst) 939
glycosaminoglycan treatment ameliorates 797
hyperlipidemia (abst) 930
lack of glomerular function reserve, GS (abst) 558
pathogenesis 613
plasma prorenin, IDDM adolescents 1154
platelet antiaggregant prevents progression (abst) 557
renal hypertrophy, TGF-/31 430
renal replacement therapy, mortality (abst) 573
tubulopathy, macroalbuminuria, primary GN 47:S-101
Dialysate
BiCart concentrate, storage (abst) 923
biocompatibility, CAPD 48:S-69
glucose, HD, protein catabolism 814
low sodium, fluid/solute transport, CAPD (abst) 1471
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lowering Ca concentration, hyperparathyroidism (abst). . 574
mesothelial cell inhibition, PD (abst) 935
partial collection, quantifies dialyzer clearance (abst) . . . 565
sterilization process and porosity (abst) 923
ultralow sodium, CAPD 333
Dialysis
adequacy techniques, compared 48:S-1 8
ethanol injection into parathyroid hyperplasia 1110
high-flux vs. paired filtration (abst) 570
high non-protein bound serum silicon (abst) 1470
lipid lowering diet, plasma lipids (abst) 941
morbidity and mortality, Nephrology Forum 1728
self-care home, elderly (abst) 930
skeletal muscle morphology, L-carnitine 1616
total body nitrogen as prognostic marker (abst) 940
Dialyzer clearance quantification (abst) 565
Dietary
essential fatty acids, NOS, fish oil supplementation.... 1280
interview by dietitian, CAPD (abst) 582
lipid restriction, plasma lipids, HD (abst) 941
phosphorus, phosphcalcium metabolism, CRF (abst)... 1243
potassium, lithiasis (abst) 1741
potassium, Na and K transport, Henle's loop 1092
protein, ACEi, proteinuria (abst) 1465
protein, bilateral ureteral obstruction 245
protein, CRF, multicenter study (abst) 561
protein, enalapril, microalbuminuria, IDDM (abst) 557
protein, phosphcalcium metabolism, CRF (abst) 1243
protein, rat remnant kidney model (abst) 925
protein, renal disease (abst) 921
protein, warm ischemic injury, rats (abst) 932
salt, BP, glucose metabolism, insulin (abst) 1739
salt, essential hypertension, kallikrein 780
salt, hypertension, L-arginine (abst) 1739
salt, NOS inhibition, renal vasoconstriction 639
salt, sympathetic activity, hypertension (abst) 1740
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